# Orforglipron (Foundayo): Evidence, Mechanism & Status

> A clinical monograph on orforglipron — the first oral, non-peptide small-molecule GLP-1 receptor agonist, FDA-approved as Foundayo in 2026 for chronic weight management, with Grade A Phase 3 RCT evidence.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Orforglipron (brand **Foundayo**) is the first **oral, non-peptide small-molecule GLP-1 receptor agonist** to clear Phase 3 and reach the U.S. market — **FDA-approved April 1, 2026** for chronic weight management. Its weight-loss and glycemic evidence is **Grade A** (large NEJM/Lancet RCTs), and it is *not* a peptide; it is cross-listed only because it competes with the GLP-1 peptides.[1](https://peptidevox.com/#r1)[5](https://peptidevox.com/#r5)

Orforglipron (development code LY3502970) is a rigid, polycyclic heteroaromatic small molecule — a once-daily pill that activates the same GLP-1 receptor as injectable semaglutide and tirzepatide, but without a single peptide bond.[13](https://peptidevox.com/#r13) It is the most clinically validated agent in this library after the GLP-1 peptides themselves, and its arrival reframes the entire oral-GLP-1 conversation. This monograph separates what the Phase 3 data prove from what remains hyped.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Orforglipron is a prescription drug with a boxed warning; dosing figures are reported strictly as seen on the FDA label and in the literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is orforglipron and how does it work?

Orforglipron is a non-peptide that entirely lacks peptide bonds, which makes it resistant to DPP-4 and protease degradation and gives it the oral stability the GLP-1 *peptides* lack.[13](https://peptidevox.com/#r13) It was originally discovered by Chugai Pharmaceutical and licensed by Eli Lilly in 2018.[1](https://peptidevox.com/#r1) Mechanistically it binds an allosteric transmembrane pocket of the GLP-1 receptor — partially overlapping but distinct from the orthosteric peptide-binding domain — and drives Gs-biased signaling through cAMP, PKA and Epac, preferentially toward metabolic efficacy over receptor internalization.[13](https://peptidevox.com/#r13)

Downstream, this produces the same physiology as the injectable GLP-1 agonists: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central-nervous-system-mediated satiety and appetite reduction.[13](https://peptidevox.com/#r13) Pharmacokinetically, oral bioavailability is about 30 to 40 percent, Tmax is roughly 2 to 4 hours, and the half-life of approximately 24 to 38 hours supports true once-daily dosing. Clearance is primarily hepatic via CYP3A oxidation, with minimal renal elimination. Critically, food has minimal impact on systemic exposure — unlike oral peptide semaglutide, which requires fasting, a sip of water and a 30-minute wait — so Foundayo can be taken any time of day with or without food or water.[1](https://peptidevox.com/#r1) As a non-peptide, it elicits no immunogenicity and no injection-site reactions.[13](https://peptidevox.com/#r13)

## What is the evidence by indication?

Unlike many compounds in this library, orforglipron's evidence base is large, pivotal and human. Multiple double-blind, placebo-controlled Phase 3 RCTs published in NEJM and The Lancet underpin its FDA approval — Grade A evidence for weight loss and glycemic control.[5](https://peptidevox.com/#r5)[7](https://peptidevox.com/#r7)

  Orforglipron evidence by indication

    IndicationBest evidenceGrade

    Obesity / overweight (chronic weight management)ATTAIN-1 (n=3,127) & ATTAIN-2, 72-wk Phase 3 RCTs; ~11.2% & ~10.5% top-dose weight lossA (human RCT)
    Type 2 diabetes (glycemic control)ACHIEVE-1/-2/-5 Phase 3 RCTs; HbA1c −1.24% to −1.48%; Frias Phase 2 (Lancet 2023)A (human RCT)
    Weight maintenance after injectablesATTAIN-MAINTAIN re-randomized SURMOUNT-5 participants; met primary endpoint (topline)A (human RCT, topline)
    Hypertension, OA pain, OSA, PAD, CV outcomesActive Phase 3 programs registered; no efficacy readout yetD→B (ongoing)

**Obesity.** ATTAIN-1 (NCT05869903), a 72-week, double-blind, placebo-controlled Phase 3 trial in 3,127 adults with obesity or overweight without diabetes, reported mean body-weight change at week 72 of negative 7.5 percent (6 mg), negative 8.4 percent (12 mg) and negative 11.2 percent (36 mg) versus negative 2.1 percent on placebo (P less than 0.001 across comparisons). At the top dose, 54.6 percent lost at least 10 percent of body weight, with concurrent improvements in waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol.[5](https://peptidevox.com/#r5)[6](https://peptidevox.com/#r6) ATTAIN-2 (NCT05872620), in obesity with type 2 diabetes, showed about 10.5 percent top-dose weight loss versus 2.2 percent placebo, and a meta-analysis pooling obese adults with and without diabetes reported roughly negative 9 to 10 percent at higher doses.[7](https://peptidevox.com/#r7)[14](https://peptidevox.com/#r14)

**Type 2 diabetes.** ACHIEVE-1 (NCT05971940), a 40-week monotherapy Phase 3 trial in 559 adults with type 2 diabetes (baseline HbA1c 8.0 percent), met its primary endpoint with HbA1c falling negative 1.24 to negative 1.48 percent across doses versus negative 0.41 percent on placebo (P less than 0.001), reaching final HbA1c of 6.5 to 6.7 percent with up to negative 7.6 percent weight loss and no severe hypoglycemia.[10](https://peptidevox.com/#r10)[11](https://peptidevox.com/#r11) ACHIEVE-2 (versus dapagliflozin) and ACHIEVE-5 (add-on to insulin glargine) both met all primary and key secondary endpoints, and the earlier Frias Phase 2 trial (Lancet 2023) established proof of concept.[12](https://peptidevox.com/#r12) The full trial registry, including the ongoing cardiovascular-outcomes study, can be reviewed at [ClinicalTrials.gov (ATTAIN-Outcomes)](https://clinicaltrials.gov/study/NCT07241390).[18](https://peptidevox.com/#r18)

Proven vs hyped
Proven (Grade A): clinically meaningful weight loss (~11–12% at top dose) and HbA1c reduction (~1.3–1.6%) in large NEJM/Lancet RCTs, culminating in FDA approval. Hyped or unproven: the broader indications — osteoarthritis, sleep apnea, hypertension, PAD and cardiovascular outcomes — have **no efficacy readouts yet** and should not be inferred.[17](https://peptidevox.com/#r17)

## What doses appear on the label and in the literature?

Reported strictly as information, not a protocol. Orforglipron is oral, once daily, any time of day, with or without food or water.[1](https://peptidevox.com/#r1) The FDA-approved Foundayo titration starts at 0.8 mg once daily, then increases at intervals of at least 30 days to 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg, escalated by tolerability and response.[4](https://peptidevox.com/#r4)[3](https://peptidevox.com/#r3) Stepwise titration exists specifically to blunt dose-dependent gastrointestinal side effects. The pivotal trials used different investigational milligram strengths — 6/12/36 mg (ATTAIN obesity) and 3/12/36 mg (ACHIEVE diabetes) — and the approved tablet strengths differ because of formulation, so trial-dose numbers are not interchangeable with label-dose numbers.[4](https://peptidevox.com/#r4)[5](https://peptidevox.com/#r5) It must not be combined with another GLP-1 receptor agonist, and as a film-coated tablet it requires no reconstitution, no refrigeration and no fasting window.[1](https://peptidevox.com/#r1)

## How safe is orforglipron?

The common adverse events at 5 percent or higher are nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, fatigue, eructation, GERD, flatulence and hair loss — dose-dependent, mostly mild to moderate, and concentrated during dose escalation.[4](https://peptidevox.com/#r4)[5](https://peptidevox.com/#r5) In ATTAIN-1, discontinuations for adverse events ran about 5 to 10 percent on orforglipron versus 3 percent on placebo; in ACHIEVE-1, 4.4 to 7.8 percent versus 1.4 percent.[10](https://peptidevox.com/#r10) Foundayo carries a class boxed warning for thyroid C-cell tumors; notably, orforglipron is not pharmacologically active in rats or mice and did not produce rodent thyroid tumors, but because it activates the human receptor and the human relevance of the class signal is undetermined, the warning applies.[4](https://peptidevox.com/#r4)

Class precautions include acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from volume depletion, hypoglycemia (chiefly with insulin or secretagogues), serious hypersensitivity, diabetic-retinopathy complications, acute gallbladder disease, and pulmonary aspiration during anesthesia.[4](https://peptidevox.com/#r4) Contraindications are a personal or family history of medullary thyroid carcinoma, MEN 2, and serious hypersensitivity. Delayed gastric emptying can affect absorption of oral co-medications, and hepatic CYP3A clearance raises a theoretical interaction with strong CYP3A modulators.[13](https://peptidevox.com/#r13) From a functional-medicine, root-cause stance, optimizing metabolic health before conception is preferable to pharmacologic weight loss during pregnancy — refer to the current FDA label for definitive guidance.[3](https://peptidevox.com/#r3)

## What is the FDA and WADA status in 2026?

Orforglipron is APPROVED as Foundayo (orforglipron) as of April 1, 2026, for chronic weight management in adults with obesity (BMI 30 or higher) or overweight with at least one weight-related comorbidity, as an adjunct to reduced-calorie diet and increased activity; the approval was supported by ATTAIN-1 and ATTAIN-2 and used the FDA Commissioner's National Priority Voucher pilot pathway.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) It is a fully approved brand-name prescription drug — not compounded and not a research chemical — and, as a single small molecule, it is not eligible for the compounding pathways that affected the GLP-1 peptides during their shortage. A type 2 diabetes indication and ex-US approvals were under review in more than 40 countries as of early 2026. It is not a DEA-controlled substance.[1](https://peptidevox.com/#r1)

For athletes the picture is currently permissive but worth watching. Orforglipron is not prohibited: the GLP-1 receptor-agonist class — semaglutide since 2024 and tirzepatide effective January 1, 2026 — sits on WADA's 2026 Monitoring Program, tracked in and out of competition for misuse patterns but not on the Prohibited List.[15](https://peptidevox.com/#r15)[16](https://peptidevox.com/#r16) As a GLP-1 receptor agonist, orforglipron falls under the same class monitoring posture and is not banned as of 2026, but athletes should confirm current status with their national anti-doping organization because monitored substances can migrate to the Prohibited List.

**Bottom line.** Orforglipron pairs genuine Grade A human evidence with a true convenience advantage: a once-daily pill, no injection, no titration-injection, and no food or water timing. Its weight loss is real but, head-to-head, somewhat lower than the top-tier injectables, and the broader indications have no efficacy readouts yet. From a metabolic, root-cause perspective, it is a powerful pharmacologic lever for genuine obesity and type 2 diabetes, but it treats the downstream state — diet quality, sleep, activity and insulin-resistance drivers remain the foundation, and the drug works best as an adjunct to, not a replacement for, those. Regulatory facts are current as of June 2026 and should be re-verified for any new indications.

---
Source: https://peptidevox.com/peptide-encyclopedia/sermaglutide-oral
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt